Circulating Endocannabinoid Levels in SARS-CoV-2 Infection and Their Potential Role in the Inflammatory Response

Overview

Journal Sci Rep

Specialty Science

Date 2024 Aug 22

PMID 39174572

Authors

Maria Velasco

Maria Posada-Ayala

Elia Perez-Fernandez

Frida Loria

Mario Amores

Jose Miguel Ramos

Elena Jaime

Carlos Guijarro

Julian Romero

Maria Ruth Pazos

Affiliations

Soon will be listed here.

Abstract

Plasma levels of endocannabinoids (eCBs) are very dynamic and variable in different circumstances and pathologies. The aim of the study was to determine the levels of the main eCBs and N-acylethanolamines (NAEs) in COVID-19 patients during the acute and post-acute phase of SARS-CoV-2 infection. Samples collected before December 31, 2020 were used for the determination of circulating eCB levels by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The association between plasma eCB measurements and biochemical and hematological parameters, as well as serum IL-6 levels, was evaluated. Samples of 64 individuals were analysed, n = 18 healthy donors, n = 30 acute, and n = 16 post-acute patients. Plasma levels of 2-arachidonoylglycerol (2-AG), were significantly elevated in COVID-19 patients when compared to healthy individuals. Plasma N-palmitoylethanolamide (PEA) and N-arachidonoylethanolamide (AEA) levels were found to be decreased in post-acute patient samples. These results suggest that 2-AG plays an important role in the inflammatory cascade in COVID-19 disease; in addition, eCBs might be involved in the post-acute pathogenesis of COVID-19. This study provides evidence of altered levels of circulating eCBs as a consequence of SARS-CoV-2 infection.

Citing Articles

Adversarial regularized autoencoder graph neural network for microbe-disease associations prediction.

He L, Zou Q, Dai Q, Cheng S, Wang Y Brief Bioinform. 2024; 25(6).

PMID: 39528423 PMC: 11554402. DOI: 10.1093/bib/bbae584.

References

Zanza C, Romenskaya T, Manetti A, Franceschi F, La Russa R, Bertozzi G . Cytokine Storm in COVID-19: Immunopathogenesis and Therapy. Medicina (Kaunas). 2022; 58(2). PMC: 8876409. DOI: 10.3390/medicina58020144. View

Akbari N, Ostadrahimi A, Tutunchi H, Pourmoradian S, Farrin N, Najafipour F . Possible therapeutic effects of boron citrate and oleoylethanolamide supplementation in patients with COVID-19: A pilot randomized, double-blind, clinical trial. J Trace Elem Med Biol. 2022; 71:126945. PMC: 8837486. DOI: 10.1016/j.jtemb.2022.126945. View

Turcotte C, Chouinard F, Lefebvre J, Flamand N . Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites. J Leukoc Biol. 2015; 97(6):1049-70. DOI: 10.1189/jlb.3RU0115-021R. View

Kozak K, Rowlinson S, Marnett L . Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J Biol Chem. 2000; 275(43):33744-9. DOI: 10.1074/jbc.M007088200. View

Lamers M, Haagmans B . SARS-CoV-2 pathogenesis. Nat Rev Microbiol. 2022; 20(5):270-284. DOI: 10.1038/s41579-022-00713-0. View

Zou S, Kumar U . Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. Int J Mol Sci. 2018; 19(3). PMC: 5877694. DOI: 10.3390/ijms19030833. View

Paland N, Pechkovsky A, Aswad M, Hamza H, Popov T, Shahar E . The Immunopathology of COVID-19 and the Cannabis Paradigm. Front Immunol. 2021; 12:631233. PMC: 7907157. DOI: 10.3389/fimmu.2021.631233. View

Tahamtan A, Tavakoli-Yaraki M, Rygiel T, Mokhtari-Azad T, Salimi V . Effects of cannabinoids and their receptors on viral infections. J Med Virol. 2015; 88(1):1-12. DOI: 10.1002/jmv.24292. View

Santa-Maria C, Lopez-Enriquez S, Montserrat-de la Paz S, Geniz I, Reyes-Quiroz M, Moreno M . Update on Anti-Inflammatory Molecular Mechanisms Induced by Oleic Acid. Nutrients. 2023; 15(1). PMC: 9824542. DOI: 10.3390/nu15010224. View

10.

Palmos A, Millischer V, Menon D, Nicholson T, Taams L, Michael B . Proteome-wide Mendelian randomization identifies causal links between blood proteins and severe COVID-19. PLoS Genet. 2022; 18(3):e1010042. PMC: 8893330. DOI: 10.1371/journal.pgen.1010042. View

11.

Harfmann E, McAuliffe T, Larson E, Claesges S, Sauber G, Hillard C . Circulating endocannabinoid concentrations in grieving adults. Psychoneuroendocrinology. 2020; 120:104801. PMC: 7348598. DOI: 10.1016/j.psyneuen.2020.104801. View

12.

Moriello A, Roviezzo F, Iannotti F, Rea G, Allara M, Camerlingo R . First Evidence of the Protective Effects of 2-Pentadecyl-2-Oxazoline (PEA-OXA) in In Vitro Models of Acute Lung Injury. Biomolecules. 2023; 13(1). PMC: 9855419. DOI: 10.3390/biom13010033. View

13.

Gouveia-Figueira S, Spath J, Zivkovic A, Nording M . Profiling the Oxylipin and Endocannabinoid Metabolome by UPLC-ESI-MS/MS in Human Plasma to Monitor Postprandial Inflammation. PLoS One. 2015; 10(7):e0132042. PMC: 4506044. DOI: 10.1371/journal.pone.0132042. View

14.

Mecha M, Feliu A, Carrillo-Salinas F, Rueda-Zubiaurre A, Ortega-Gutierrez S, Garcia de Sola R . Endocannabinoids drive the acquisition of an alternative phenotype in microglia. Brain Behav Immun. 2015; 49:233-45. DOI: 10.1016/j.bbi.2015.06.002. View

15.

Matias I, Gonthier M, Petrosino S, Docimo L, Capasso R, Hoareau L . Role and regulation of acylethanolamides in energy balance: focus on adipocytes and beta-cells. Br J Pharmacol. 2007; 152(5):676-90. PMC: 2190005. DOI: 10.1038/sj.bjp.0707424. View

16.

Rossi F, Tortora C, Argenziano M, Di Paola A, Punzo F . Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?. Int J Mol Sci. 2020; 21(11). PMC: 7312493. DOI: 10.3390/ijms21113809. View

17.

de Carvalho J, da Silva-Neto P, Toro D, Fuzo C, Nardini V, Pimentel V . The Interplay among Glucocorticoid Therapy, Platelet-Activating Factor and Endocannabinoid Release Influences the Inflammatory Response to COVID-19. Viruses. 2023; 15(2). PMC: 9959303. DOI: 10.3390/v15020573. View

18.

Esposito G, Pesce M, Seguella L, Sanseverino W, Lu J, Corpetti C . The potential of cannabidiol in the COVID-19 pandemic. Br J Pharmacol. 2020; 177(21):4967-4970. PMC: 7300643. DOI: 10.1111/bph.15157. View

19.

Gomez-Escobar L, Hoffman K, Choi J, Borczuk A, Salvatore S, Alvarez-Mulett S . Cytokine signatures of end organ injury in COVID-19. Sci Rep. 2021; 11(1):12606. PMC: 8206105. DOI: 10.1038/s41598-021-91859-z. View

20.

Patsenker E, Sachse P, Chicca A, Gachet M, Schneider V, Mattsson J . Elevated levels of endocannabinoids in chronic hepatitis C may modulate cellular immune response and hepatic stellate cell activation. Int J Mol Sci. 2015; 16(4):7057-76. PMC: 4425004. DOI: 10.3390/ijms16047057. View